{
    "ticker": "OCSAW",
    "name": "Ocuphire Pharma, Inc.",
    "description": "Ocuphire Pharma, Inc. is a biopharmaceutical company focused on the development of innovative therapies for the treatment of ophthalmic diseases. Founded in 2018, the company is dedicated to addressing unmet medical needs in eye care, particularly in areas such as presbyopia and diabetic retinopathy. Ocuphire's lead product candidates include Nyxol, a novel drop designed for the treatment of presbyopia and other conditions, and APX330, aimed at addressing diabetic retinopathy. The company's approach combines advanced drug delivery technologies with a commitment to rigorous clinical research, ensuring that its therapies are both safe and effective. Ocuphire is led by a team of experienced professionals with deep expertise in drug development and commercialization. The company is actively engaged in clinical trials to validate its product candidates and is committed to bringing its innovative therapies to market to improve patient outcomes and enhance the quality of life for individuals suffering from vision-related conditions. With a strong pipeline and a focus on patient-centric solutions, Ocuphire Pharma is poised to make significant contributions to the field of ophthalmology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Chicago, Illinois, USA",
    "founded": "2018",
    "website": "https://ocuphire.com",
    "ceo": "M. E. O'Brien",
    "social_media": {
        "twitter": "https://twitter.com/OcuphirePharma",
        "linkedin": "https://www.linkedin.com/company/ocuphire-pharma/"
    },
    "investor_relations": "https://ocuphire.com/investors",
    "key_executives": [
        {
            "name": "M. E. O'Brien",
            "position": "CEO"
        },
        {
            "name": "Dr. Robert C. Dempsey",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Ophthalmic Therapies",
            "products": [
                "Nyxol",
                "APX330"
            ]
        }
    ],
    "seo": {
        "meta_title": "Ocuphire Pharma, Inc. | Innovative Ophthalmic Therapies",
        "meta_description": "Explore Ocuphire Pharma, Inc., a biopharmaceutical company dedicated to developing innovative therapies for ophthalmic diseases like presbyopia and diabetic retinopathy.",
        "keywords": [
            "Ocuphire Pharma",
            "Ophthalmology",
            "Biopharmaceuticals",
            "Presbyopia Treatment",
            "Diabetic Retinopathy"
        ]
    },
    "faq": [
        {
            "question": "What does Ocuphire Pharma specialize in?",
            "answer": "Ocuphire Pharma specializes in developing innovative therapies for ophthalmic diseases."
        },
        {
            "question": "Who is the CEO of Ocuphire Pharma?",
            "answer": "M. E. O'Brien is the CEO of Ocuphire Pharma, Inc."
        },
        {
            "question": "Where is Ocuphire Pharma headquartered?",
            "answer": "Ocuphire Pharma is headquartered in Chicago, Illinois, USA."
        },
        {
            "question": "What are Ocuphire's main products?",
            "answer": "Ocuphire's main products include Nyxol and APX330."
        },
        {
            "question": "When was Ocuphire Pharma founded?",
            "answer": "Ocuphire Pharma was founded in 2018."
        }
    ],
    "competitors": [
        "RETA",
        "EYPT",
        "RGEN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "BIIB"
    ]
}